MedTrace Logo

A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.

NCT00283218 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2006-08-08

No results posted yet for this study

Summary

The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin analogues will improve post prandial glycaemic control in patients with type 1 diabetes.

OBJECTIVE:

The objective is to describe pharmacodynamic (PD) and pharmacokinetic (PK) profiles of Insulin Aspart (IAsp), Biphasic Insulin Aspart (BIAsp) 30, 50 and 70 for a period of 12 hours following a standard test meal on four days respectively in subjects with type 1 diabetes.

Conditions

Interventions

DRUG

NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70

Sponsors & Collaborators

Principal Investigators

  • Jens S Christiansen, M.D. · Medicinsk Afd. M, Århus Sygehus, Nørrebrogade 44, 8000 Århus C

  • Tina Parkner, M.D. · Medicinsk Afd. M, Århus Sygehus, Nørrebrogade 44, 8000 Århus C

  • Niels Ejskjaer, M.D. · Medicinsk afd. M, Århus Sygehus, Nørrebrogade 44, 8000 Århus C

  • Rannveig L Thorisdottir, Stud.med · Medicinsk afd. M, Århus Sygehus, Nørrebrogade 44, 8000 Århus C

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2006-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283218 on ClinicalTrials.gov